Deepak Voora
Deepak Voora
Duke University Medical Center
Verified email at
Cited by
Cited by
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ...
Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008
The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
D Voora, SH Shah, I Spasojevic, S Ali, CR Reed, BA Salisbury, ...
Journal of the American college of cardiology 54 (17), 1609-1616, 2009
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update
LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ...
Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy
RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ...
Clinical Pharmacology & Therapeutics 92 (1), 112-117, 2012
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
D Voora, C Eby, MW Linder, PE Milligan, BL Bukaveckas, HL McLeod, ...
Thrombosis and haemostasis 93 (04), 700-705, 2005
Genetic-based dosing in orthopedic patients beginning warfarin therapy
EA Millican, PA Lenzini, PE Milligan, L Grosso, C Eby, E Deych, G Grice, ...
Blood, The Journal of the American Society of Hematology 110 (5), 1511-1515, 2007
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
LH Cavallari, CR Lee, AL Beitelshees, RM Cooper-DeHoff, JD Duarte, ...
JACC: Cardiovascular Interventions 11 (2), 181-191, 2018
Phenotype standardization for statin‐induced myotoxicity
A Alfirevic, D Neely, J Armitage, H Chinoy, RG Cooper, R Laaksonen, ...
Clinical Pharmacology & Therapeutics 96 (4), 470-476, 2014
A host-based RT-PCR gene expression signature to identify acute respiratory viral infection
AK Zaas, T Burke, M Chen, M McClain, B Nicholson, T Veldman, EL Tsalik, ...
Science translational medicine 5 (203), 203ra126-203ra126, 2013
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
D Voora, DC Koboldt, CR King, PA Lenzini, CS Eby, R Porche‐Sorbet, ...
Clinical Pharmacology & Therapeutics 87 (4), 445-451, 2010
The pharmacogenetics of coumarin therapy
D Voora, HL McLeod, C Eby, BF Gage
Future Medicine Ltd 6 (5), 503-513, 2005
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
C Varenhorst, N Eriksson, Å Johansson, BJ Barratt, E Hagström, ...
European heart journal 36 (29), 1901-1912, 2015
Clinical application of cardiovascular pharmacogenetics
D Voora, GS Ginsburg
Journal of the American College of Cardiology 60 (1), 9-20, 2012
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response
D Voora, SH Shah, CR Reed, J Zhai, DR Crosslin, C Messer, ...
Circulation: Cardiovascular Genetics 1 (2), 100-106, 2008
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics
AL Beitelshees, D Voora, JP Lewis
Pharmacogenomics and Personalized Medicine 8, 43, 2015
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events
D Voora, D Cyr, J Lucas, JT Chi, J Dungan, TA McCaffrey, R Katz, ...
Journal of the American College of Cardiology 62 (14), 1267-1276, 2013
The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real‐world setting
LH Cavallari, AL Beitelshees, KV Blake, LG Dressler, JD Duarte, A Elsey, ...
Clinical and translational science 10 (3), 143, 2017
Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter‐directed atrial fibrillation ablation
TW Wallace, BD Atwater, JP Daubert, D Voora, AL Crowley, TD Bahnson, ...
Journal of cardiovascular electrophysiology 21 (8), 849-852, 2010
The pharmacogenetics of antiplatelet agents: towards personalized therapy?
T Ahmad, D Voora, RC Becker
Nature Reviews Cardiology 8 (10), 560-571, 2011
Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy
RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ...
Clin Pharmacol Ther 92 (1), 112-117, 2012
The system can't perform the operation now. Try again later.
Articles 1–20